The balance between androgens and estrogens is very important in the development of the prostate, and even small changes in estrogen levels, including those of estrogen-mimicking chemicals, can lead to serious changes. Bisphenol A (BPA), an endocrine-disrupting chemical, is a well-known, ubiquitous, estrogenic chemical. To investigate the effects of fetal exposure to low-dose BPA on the development of the prostate, we examined alterations of the in situ sex steroid hormonal environment in the mouse urogenital sinus (UGS). In the BPAtreated UGS, estradiol (E 2 ) levels and CYP19A1 (cytochrome P450 aromatase) activity were significantly increased compared with those of the untreated and diethylstilbestrol (DES)-treated UGS. The mRNAs of steroidogenic enzymes, Cyp19a1 and Cyp11a1, and the sex-determining gene, Nr5a1, were upregulated specifically in the BPA-treated group. The upregulation of mRNAs was observed in the mesenchymal component of the UGS as well as in the cerebellum, heart, kidney, and ovary but not in the testis. The number of aromatase-expressing mesenchymal cells in the BPA-treated UGS was approximately twice that in the untreated and DEStreated UGS. The up-regulation of Esrrg mRNA was observed in organs for which mRNAs of steroidogenic enzymes were also up-regulated. We demonstrate here that fetal exposure to lowdose BPA has the unique action of increasing in situ E 2 levels and CYP19A1 (aromatase) activity in the mouse UGS. Our data suggest that BPA might interact with in situ steroidogenesis by altering tissue components, such as the accumulation of aromatase-expressing mesenchymal cells, in particular organs.
INTRODUCTION
Endocrine-disrupting chemicals (EDCs) have been implicated in the alteration of fetal development of urogenital organs as well as the reproductive and endocrine systems in humans and other species [1] . The fetal development of urogenital organs is induced by endogenous hormonal messages that originate in fetal and maternal hormone systems. Fetal exposure to EDCs disrupts the interactions between endogenous hormones and their receptors, causing adverse effects later in life [2] . In the prostate, both androgens and estrogens play a significant role in development and differentiation as well as in the maintenance of adult homeostasis [3] . Therefore, even small changes in estrogen levels, including those of estrogen-mimicking chemicals, can lead to changes in prostate development and differentiation.
Bisphenol A (BPA), one of the EDCs, is a well-known, ubiquitous, estrogenic chemical used in the manufacture of polycarbonate plastics, as a lining in metal food and drink cans, and in dental sealants [4] . The concern with BPA originates from its detection in maternal and fetal plasma as well as the placenta [5, 6] . Thus, fetal exposure to BPA is implicated in fetal toxicity as well as in subsequent growth of the infant. Histopathologically, fetal exposure to low-dose BPA (10 lg kg À1 day À1 ) has been shown to increase cell proliferation of urogenital sinus epithelium (UGE) in the primary prostatic ducts of CD1 mice [7] . Recently, our group reported that fetal exposure to low-dose BPA (20 lg kg À1 day À1 ) specifically increased the number of basal epithelial cells in the adult prostate of BALB/c mice and also induced permanent cytokeratin 10 expression in such cells similar to the effects of synthetic estrogen diethylstilbestrol (DES; 0.2 lg kg À1 day À1 ) [8] . Epigenetically, neonatal exposure of male rats to low-dose BPA (10 lg kg À1 day À1 ) elicited critical molecular changes during prostate development and also increased prostatic gland susceptibility to precancerous neoplastic lesions and hormonal carcinogenesis [9] . Toxicological studies of BPA at less than 50 lg kg À1 day À1 in rodent fetuses and offspring have demonstrated alterations of mammary gland development, open-field behavior, and reproductive functioning [10] [11] [12] .
Some EDCs are reported to alter the in situ sex steroid hormonal environment in the reproductive system. The triazine herbicide atrazine binds directly to adrenal-4-binding protein/ steroidogenic factor-1 (official symbol NR5A1) and increases CYP19A1 (cytochrome P450 aromatase) expression and, ultimately, estradiol (E 2 ) production in human genital cancer cell lines [13] . The aryl hydrocarbon (dioxin) also increases CYP19A1 (aromatase) expression mediated by its receptor in mouse ovaries [14] . In contrast, the phosphorothioate insecticide profenofos increases the expression of steroidogenic genes and testosterone levels in rat testes [15] . Recently reported adverse effects of BPA on in situ steroidogenesis include increased testosterone levels in mouse Leydig cells and decreased E 2 levels in porcine ovarian granulosa cells [16, 17] . Thus, BPA may have the potential not only to mimic estrogenic action but also to alter in situ steroidogenesis in the prostate as well as other reproductive organs.
To investigate the effects of fetal exposure to low-dose BPA on in situ steroidogenesis in the developing prostate, we first measured sex steroid hormone levels and CYP19A1 (aromatase) activity in the BPA-treated mouse urogenital sinus (UGS), from which the prostate develops embryologically. Subsequently, we examined the alterations of steroidogenic enzyme gene expression to confirm the alterations of the in situ sex steroid hormonal environment in the BPA-treated mouse UGS. Finally, we identified the BPA-specific biological effects for in situ steroidogenesis during fetal prostate development.
MATERIALS AND METHODS

Animals
In the present study, 36 pregnant female C57BL/6 mice were purchased on the 12th day of gestation from Japan SLC, where the breeding strategy was to mate three female C57BL/6 mice (age, 10 wk) with one male overnight and separate them the next morning (plug date denoted as Day 0). All animals were housed individually in chip-bedded polyolefin cages in a room with controlled temperature (23 6 18C) and humidity (45 to 65%) on a 12L:12D photoperiod. Mice were fed a low-phytoestrogen diet (NIH-07PLD; Oriental Yeast Co.) and tap water ad libitum.
Chemicals
For the present study, both BPA and DES with a purity of 99% or greater were purchased from Nacalai Tesque and Wako Pure Chemical Industries, respectively.
Fetal Exposure to Chemicals
We randomly assigned 36 pregnant female C57BL/6 mice to three different treatment groups: BPA (20 lg kg À1 day À1 , n ¼ 12) or DES (0.2 lg kg À1 day
À1
, n ¼ 12), both of which were dissolved in tocopherol-stripped corn oil (MP Biomedical, Inc.), administered by oral gavages on Embryonic Day (E) 13 to E16 and the control group, in which pregnant mice were fed tocopherolstripped corn oil (2 ml/kg, n ¼ 12). Previously, our group reported that this protocol of fetal exposure to BPA and DES resulted in similar histopathological changes of adult prostate-that is, increased basal epithelial cell number and induction of cytokeratin 10, a classic marker associated with squamous differentiation, in such cells [8] . Our dose level of BPA for the present study was also based on reported results suggesting that BPA is less than 100-fold less potent than DES. The Mie University's Committee on Animal Investigation approved the experimental protocol.
Termination and UGS Dissection
Between E17 and Postnatal Day (P) 1, all animals were terminated by an overdose of isoflurane followed by cervical dislocation. For each of the three groups, from 15 to 18 fetuses (both male and female) from three pregnant mice were collected at E17, E18, P0, and P1. The bladder and urethra were removed and dissected to isolate the UGS, and then the five or six UGS obtained were pooled as one sample. Thus, the 15-18 UGS were divided into three samples at each time point. The UGS, cerebellum, heart, kidney, testis, and ovary were collected in RNAlater (Applied Biosystems).
To isolate pure UGS, other tissues, such as the bladder, urethra, wolffian duct, seminal vesicle, and mullerian duct, were removed from both the male and female urogenital tracts. The histopathology of the mouse UGS was then examined by hematoxylin-and-eosin staining.
Measurements of In Situ E 2 Levels and CYP19A1 (Aromatase) Activity in UGS
The E 2 levels and CYP19A1 (aromatase) activity in UGS were determined by liquid chromatography-tandem mass spectrometry [18] and a tritiated water release assay [19] , respectively, which were made available by Aska Pharma Medical. Briefly, the organs were homogenized, and the extracts were applied to a C18 Amprep solid-phase column (Amersham Biosciences) to remove contaminating fats. The E 2 was then separated using a normal-phase highperformance liquid chromatography system (Jasco) with a silica gel column (Cosmosil 5SI; Nacalai Tesque), and 100 pg of isotope-labeled [ 13 C 4 ]E 2 were added to extracts. The evaporated extracts were reacted with 5% pentafluorobenzyl bromide/acetonitrile, under KOH/ethanol, for 1 h at 558C. After evaporation, the products were reacted with 100 ml of picolinic acid solution (2% picolinic acid, 2% 2-dimethylaminopyridinc, and 1% 2-methyl-6-nitrobenzoic acid in tetrahydrofuran) and 20 ml of triethylamine for 0.5 h at room temperature. The reaction products were dissolved in 1% acetic acid and then purified using a Bond Elute C18 column (Varian). The products were measured with a reverse-phase liquid chromatograph (Agilent 1100; Agilent Technologies) coupled with an API 5000 triple-stage quadrupole mass spectrometer (Applied Biosystems) in the positive-ion mode. This device monitored the m/z 558 to m/z 339 (E 2 ) and m/z 562 to m/z 343 ([ 13 C 4 ]E 2 ) transitions. The tritiated water release assay was used for the measurement of CYP19A1 (aromatase) activity. This method measures the production of 3 H 2 O, which forms as a result of aromatization of the substrate [1b-
3 H]androst-4-ene-3,17-dione (New England Nuclear). Serum-free medium containing [1b- 3 H]androst-4-ene-3,17-dione solution (54 nM) was prepared, of which 0.5 ml was added to each sample. After incubation for 1 h, the samples were placed on ice, and 200 ll of culture medium were withdrawn. The medium was extracted with 500 ll of chloroform, vortexed, and then centrifuged for 1 min at 9000 3 g. A 100-ll aliquot of the aqueous phase was mixed with 100 ll of a 5% (wt/vol) charcoal/0.5% (wt/vol) dextran T-70 suspension, vortexed, and then incubated at room temperature for 10 min. Then, after centrifugation of the solution for 5 min at 9000 3 g, a 150-ll aliquot was removed for measurement of radioactivity by liquid scintillation.
RNA Extraction and cDNA Preparation
Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Inc.) in accordance with the manufacturer's instructions. The RNA concentration was then determined spectrophotometrically by a multidetection microplate reader (Dainippon Sumitomo Pharma Co.). From 50 ng of total RNA, cDNA was reverse transcribed using oligo(dT) and Superscript II RNase H-reverse transcriptase (Invitrogen) as previously described [8] .
Analysis of Gene Expression Profile
For determining gene expression profiles of the male UGS, GeneChip analysis with the Percellome method was performed [20] . Briefly, organs were prepared using RLT buffer (Qiagen, Inc.). Total RNA was extracted using RNeasy Mini Kit. First-strand cDNA was synthesized by incubating 5 mg of total RNA with a T7 oligo(dT) primer (Invitrogen) according to the manufacturer's protocol. The dsDNA was mixed with T7 RNA polymerase (Enzo Biochem, Inc.). During the in vitro transcription, generated cRNAs were labeled with biotin-16-UTP and biotin-11-CTP (Enzo Biochem, Inc.). The purified cRNA was fragmented at 300-500 bp into the target solution. Hybridization was performed with the GeneChip Mouse Genome 430 Version 2.0 (Affymetrix, Inc.) at 458C for 18 h after staining with streptavidin-Rphycoerythrin conjugates (Molecular Probes, Invitrogen). The reacted arrays were then scanned as digital image files, and the scanned data were analyzed with GeneChip Operating Software (Affymetrix, Inc.). The expression data were converted to copy numbers of mRNA per cell by the Percellome method, quality controlled, and analyzed using Percellome software [20] .
Real-Time PCR Analysis
Real-time PCR was carried out in the iCycler iQ Detection System (BioRad Laboratories) with iQ SYBR-Green Supermix reagents (Bio-Rad Laboratories) as previously described [8] . The PCR amplification reaction was performed with specific primers as shown in Table 1 . After PCR, meltingcurve analysis was performed to verify specificity and identity of the PCR products. All data were analyzed with the iCycler iQ Optical System Software Version 3.0A (Bio-Rad Laboratories). All PCR data were normalized to Gapdh mRNA.
Preparation of Primary Cultured Mesenchymal Cells from UGS
The UGS were dissected from the fetuses and separated into UGE and urogenital sinus mesenchyme (UGM) by tryptic digestion and mechanical separation as previously described [21] . UGM were cultured in RPMI-1640 BPA INCREASES ESTROGEN PRODUCTION with 5% fetal bovine serum and plated out on four-well glass slides (BD Falcon). After several days, cells were fixed in methanol and processed for immunocytochemical analysis.
Immunocytochemical Staining
The sections were first incubated for 15 min in 0.01 M PBS. After inhibition of endogenous peroxidases (10 min in 0.6% H 2 O 2 diluted in 0.01 M PBS plus 0.2% Triton X-100 [PBST]) and saturation (2 h in a 5% normal goat serum solution), sections were incubated overnight at 48C in a polyclonal affinity-purified antiaromatase antibody or estrogen-related receptor gamma (ESRRG) antibody raised in rabbit against quail recombinant aromatase or ESRRG diluted 1:500 in 0.01 M PBST. The next day, the sections were immersed for 2 h at room temperature in a biotin-conjugated goat anti-rabbit immunoglobulin G (DakoCytomation, Inc.) diluted 1:400 in PBST and then for 2 h in a streptavidin-fluorescein complex (Rhodamine; DakoCytomation, Inc.) diluted 1:50 in PBST. Between each step, sections were extensively rinsed in PBST. The sections were mounted onto microscope slides, coverslipped with a gelatin-based mounting medium, and stored in the dark at 48C. For doublelabeling immunofluorescence, Alexa Fluor 488-or 594-conjugated secondary antibodies were used. Rabbit polyclonal anti-aromatase antibody was kindly provided by Prof. Nobuhiro Harada (Department of Biochemistry, Fujita Health University School of Medicine, Aichi, Japan) [22] . The rabbit polyclonal anti-ESRRG antibody used in the present study was established and characterized as previously reported [23] . The mouse monoclonal anti-Ran antibody (Santa Cruz Biotechnology, Inc.) was used to detect nucleus in cells. Ran, also called TC4, is the small RAS-related protein that is localized in the nucleus.
Statistical Analysis
Results are expressed as the mean 6 SD. Differences among the three groups were determined using Student t-test with Dunnett multiple comparison. A value of P , 0.05 was considered to be statistically significant.
RESULTS
BPA-Specific Increases of E 2 Levels and CYP19A1 (Aromatase) Activity in Mouse UGS
The pregnant mice were exposed to low-dose BPA during the onset of prostatic budding (E13-E16), and the UGS of fetuses were collected during bud elongation (E17-P1). In analyses of in situ sex steroid hormonal environment, E 2 levels and CYP19A1 (aromatase) activity were significantly increased only at P1 in BPA-treated UGS, not at P1 in the DES-treated UGS (Fig. 1) . At E17 and P1, both the E 2 levels and CYP19A1 (aromatase) activity in untreated male UGS were not significantly different compared with those in untreated female UGS.
BPA-Specific Up-Regulation of Steroidogenic Enzyme and Sex-Determining Gene mRNA in Mouse UGS
To investigate the BPA-specific gene alterations related to increases of the E 2 levels and aromatase activity, we performed preliminary GeneChip analysis with the Percellome method in the BPA-or DES-treated male UGS at E17 and P1. The results showed BPA-specific mRNA up-regulation of steroidogenic enzymes, such as Cyp11a1, Cyp11b1, and Cyp17a1, and sexdetermining factors, such as Nr5a1, Nr0b1, Gata4, and Amhr2 (data not shown). Furthermore, quantitative PCR analysis confirmed the mRNA up-regulation of Cyp19a1, Cyp11a1, and Nr5a1 only in the BPA-treated neonatal (P0 and P1) UGS, not in the DES-treated neonatal UGS (Fig. 2) . No difference in mRNA expression levels was found between E17 and P1 when comparing the untreated male UGS to that of the female. In untreated male and female UGS, the mRNA of Cyp19a1 was gradually increased between E17 and P1.
Restricted BPA-Specific Up-Regulation of Steroidogenic Enzyme and Sex-Determining Gene mRNA in UGE and UGM
In male fetuses at P1, it was not feasible to separate UGE and UGM components within the male UGS because of the formation of prostatic buds. In the female at P1, the up-regulation of Cyp19a1, Cyp11a1, and Nr5a1 mRNA was observed only in UGM, not in UGE, of the BPA-treated group (Fig. 3) . In both male and female UGE, expressions of such mRNAs were quite low and not up-regulated, even in the BPA-treated group. At E17, no difference in mRNA expression levels was found when comparing the untreated male UGM with that of the female.
BPA-Specific Increases of Aromatase-Expressing Cells in Primary Cultured UGM
In both the male and female, P1 UGM was primary cultured in vitro. Representative pictures of aromatase-positive cells are shown in Figure 4 , A-C. The aromatase-positive staining was FIG. 2 . BPA-specific up-regulation of steroidogenic enzyme and sex-determining gene mRNA in mouse UGS. The relative mRNA expressions of Cyp19a1 (A), Cyp11a1 (B), and Nr5a1 (C) were determined in the untreated control (open bar), BPA-treated UGA (closed bar), and DEStreated UGS (slashed bar) between E17 and P1. *P , 0.05, **P , 0.01, ***P , 0.001 vs. control at each time point; P , 0.01, P , 0.001 vs. control at E17.
observed in the cytoplasm of cultured UGM. The rate of positivity (i.e., the percentage of cells that expressed CYP19A1
[aromatase] protein), was approximately 10% in the untreated and the DES-treated groups, whereas it was as high as approximately 30% in the BPA-treated group (Fig. 4D) . No difference in the rate of positivity of CYP19A1 (aromatase) was found when comparing the untreated male UGM to that of the female.
Restricted BPA-Specific Up-Regulation of Esrrg mRNA in UGE and UGM In E17 female UGM, the mRNA expression of Esr1 was upregulated by both BPA and DES treatment (Fig. 5A) . At E17, however, the mRNA expression of Ar was up-regulated by both BPA and DES treatment in the male UGS (Fig. 5B) . At P1, mRNA expression of Ar was up-regulated by both BPA and DES treatment in the female UGS (Fig. 5B) . In both the male and female, the up-regulation of Esrrg mRNA was observed at E17 and restricted in UGM, but not in UGE, of the BPA-treated group (Fig. 5C) . In both the male and female UGE, the expression of Esrrg mRNA was quite low and not up-regulated, even in the BPA-treated group. At E17, no difference in mRNA expression levels was found when comparing the untreated male UGS with that of the female.
BPA-Specific Increases of ESRRG-Expressing Cells in Primary Cultured UGM
In both the male and female, E17 UGM was primary cultured in vitro. Representative pictures of ESRRG-positive cells are shown in Figure 6 , A-C. The ESRRG-positive staining was observed in both the nucleus and the cytoplasm of cultured UGM. The number of ESRRG-positive UGM was significantly increased only in the BPA-treated group and showed a 2.2-fold increase in males and a 1.6-fold increase in females (Fig. 6D) . No difference was found in the rate of positivity of ESRRG when comparing the untreated male UGM with that of the female.
BPA-Specific Up-Regulation of Esrrg and Steroidogenic Enzyme mRNA in Sex Hormone-Related Organs
To investigate the BPA-specific up-regulation of in situ steroidogenesis in other organs, we first examined the changes in Esrrg mRNA expression in sex hormone-related organs, such as the cerebellum, heart, kidney, ovary, and testis. At P1, the mRNA expression of Esr1 in the cerebellum, heart, kidney, and ovary, but not in the testis, was up-regulated by both BPA and DES treatment (Fig. 7A) . However, no significant difference in Ar mRNA expression was observed in all organs examined (Fig. 7B) . In the untreated group, the mRNA expression of Esrrg was not detected in the testis at E17 and P1 (Fig. 7C) . The up-regulation of Esrrg mRNA was observed at E17 and restricted to the cerebellum, heart, kidney, and ovary (Fig. 7C) . The BPA-specific up-regulation of Cyp19a1, Cyp11a1, and Nr5a1 mRNA was observed only at P1 in the cerebellum, heart, kidney, and ovary, but not in the testis (Fig.  8) .
DISCUSSION
Concern about the effects of EDCs such as BPA on human health has been increasing [24] . Although the majority of EDCs have the potential to alter functioning of the reproductive and endocrine system, the actual mechanism responsible for such alterations has not been identified thoroughly. BPA is of concern because its chemical structure resembles that of DES. Several studies have reported that BPA can mimic estrogen action, such as induction of vaginal cornification, uterine vascular permeability, growth and differentiation of the mammary gland, and synaptic plasticity in the hippocampus [25] [26] [27] [28] . In the prostate, alterations in normal development can produce permanent changes that persist throughout adulthood and may increase the risk of disease in later life [9] . Thus, our objective was to investigate the biological effects of low-dose BPA on the initial development of primary ducts in the fetal prostate.
During prostatic development, alteration of sex steroid hormone synthesis may be responsible for prostatic anomalies associated with fetal exposure to EDCs. In the present study, fetal exposure to low-dose BPA increased E 2 levels in P1 UGS of both the male and female, whereas DES-induced changes were not detected. This alteration was also correlated with increased activity of CYP19A1 (aromatase) in UGS at P1, suggesting the unique action of BPA for in situ steroidogenesis in UGS. The BPA-specific increase of E 2 levels in UGS at P1 was correlated with the following: mRNA up-regulation of steroidogenic enzymes, such as Cyp19a1 and Cyp11a1, and an increased number of aromatase-expressing UGM. The enzyme CYP19A1 (aromatase) is responsible for in situ E 2 production and the crucial testosterone/E 2 balance necessary for normal embryonic and fetal development, even in males. The data presented here shows that the up-regulation of Cyp19a1 mRNA in BPA-treated UGM was comparable to changes in both in situ E 2 production and CYP19A1 (aromatase) activity.
In the present study, we demonstrated that the BPA-specific increase in steroidogenic enzyme mRNA and aromataseexpressing cell number were observed in both the male and female UGM. During embryonic development, the mesenchymal component is involved in the induction and organogenesis of various organs, including the prostate, mammary gland, lung, kidney, and pancreas. It has been well established that subpopulations of the mesenchymal component are a source of potent molecules that regulate epithelial growth and differentiation [29] . In the prostate, androgen-responsive signals derived from UGM permissively and instructively induce UGE to form primary ducts of the prostate [30] .
Comparison between the neonatal male and female UGS shows a similarity in the condensed mesenchyme of the ventral areas-that is, the ventral prostate mesenchyme (VPM) in the male and the ventral mesenchymal pad (VMP) in the female [31] . In the male, a defined VPM is specifically associated with ductal branching morphogenesis and cytodifferentiation of the ventral prostate. Females do not usually form a prostate. In a tissue recombination model, the female VMP induces prostate development in response to androgens [32] , suggesting that cells within the female VMP have prostatic-inductive activity. Moreover, an earlier tissue recombination study showed that the ability of the female UGS to respond to androgens in forming prostate was gradually lost between P1 and P5 [33] . These results suggest strongly that androgen-responsive regulatory molecules are expressed constitutively even in the female VMP. Although the female VMP forms in the absence of androgens, androgen receptor (AR) expression was observed in the neonatal female VMP in a pattern similar to that observed in the male VPM [34] . Therefore, the BPA-specific increase in E 2 levels might interact with the intracellular AR signaling in both the male VPM and the female VMP. However, to our knowledge, FIG. 8 . BPA-specific up-regulation of steroidogenic enzyme and sex-determining gene mRNA in sex steroid hormone-related organs. The relative mRNA expressions of Cyp19a1 (A), Cyp11a1 (B), and Nr5a1 (C) were determined in sex steroid hormonerelated organs of the untreated control (open bar), BPA-treated UGS (closed bar), and DES-treated UGS (slashed bar) at E17 and P1. C, cerebellum; H, heart; K, kidney; O, ovary; T, testis. *P , 0.05, **P , 0.01, ***P , 0.001 vs. control. FIG. 7 . BPA-specific up-regulation of Esrrg mRNA in sex steroid hormone-related organs. The relative mRNA expressions of Esr1 (A), Ar (B), and Esrrg (C) were determined in sex steroid hormone-related organs of the untreated control (open bar), BPA-treated UGS (closed bar), and DEStreated UGS (slashed bar) at E17 and P1. C, cerebellum; H, heart; K, kidney; O, ovary; T, testis; n.d., not detected. *P , 0.05, **P , 0.01, ***P , 0.001 vs. control.
the morphological changes in neonatal female UGS have not yet been investigated.
Our results suggest that BPA has a stimulatory effect on in situ steroidogenesis in P1 UGS of both the male and female at low-dose exposure levels. Recently, ESRRG has been reported to bind strongly with BPA [35] . Susens et al. [36] have reported that expression of ESRRG in the mouse is organspecific: ESRRG is expressed in the brain, heart, kidney, and skeletal muscle but not in the lung, spleen, and testis. In the present study, the up-regulation of Cyp19a1 and Cyp11a1 mRNA by BPA treatment was detected only in organs expressing Esrrg mRNA. These data suggest that the possibility of a stimulatory effect on in situ steroidogenesis by fetal exposure to low-dose BPA may be a concern not only in UGS but also in organs expressing ESRRG, such as the brain, heart, kidney, and ovary. It is important to note that Takeda et al. [23] have recently reported that ESRRG was detected in the human testis, suggesting that the distribution of ESRRG differs slightly between mice and humans.
In the present study, the BPA-specific up-regulation of steroidogenic enzyme mRNA in UGS, cerebellum, heart, kidney, and ovary was observed only during the neonatal period (i.e., P0 and P1) and not during the prenatal period (i.e., E17 and E18). During pregnancy in rodents, large amounts of estrogens produced in the maternal ovaries are continuously delivered to the fetus through the placenta. After birth, however, the fetus may be released from the maternal, highestrogen environment. Thus, one possibility is that the maternal, high-estrogen environment in pregnancy may protect the fetus from the effect of BPA on in situ steroidogenesis during the prenatal period. However, we did not investigate the effects of neonatal BPA treatment on in situ steroidogenesis.
The EDC-induced alterations of the in situ estrogen environment depend on each compound. In addition to atrazine and dioxin, the organotin compound tributyltin also increases E 2 production in human placental choriocarcinoma cells [37] . Tributyltin has been demonstrated to induce the superimposition of male sex organs, such as a penis and/or a vas deferens, over female sex organs, which is a phenomenon known as imposex [38] . These studies suggest strongly that EDCs might affect fetal development not only by mimicking the actions of sex steroid hormones but also by alteration of in situ steroidogenesis.
In the prostate, AR expressed in mesenchyme is required for directing growth and branching morphogenesis of epithelia, presumably by induction of growth factors [39] . In the present study, fetal exposure to BPA or DES increased Ar mRNA expression in E17 UGM of the male, whereas Esr1 mRNA expression was up-regulated in E17 UGM of the female. Recently, Richter et al. [40] have reported that in vitro BPA treatment stimulates Ar and Esr1 mRNA expression in mesenchymal cells isolated from fetal mouse prostate. Thus, our results support the idea that BPA-induced cell proliferation of the primary prostatic ducts may be caused by inducing Ar mRNA expression in the male UGM. In contrast, the induction of Esr1 mRNA expression by BPA or DES may create a positive-feedback loop in the female UGM. Further investigation and morphological analysis will be necessary to confirm the effects of up-regulated ESR1 in the female UGS.
In conclusion, we have shown the unique action of BPA in the mouse UGS. Specifically, we have demonstrated that the increases in E 2 levels and CYP19A1 (aromatase) activity were observed in the BPA-treated UGS but not in the DES-treated UGS. Ricke et al. [41] have recently reported that stromal hormone imbalance, a potential source of local E 2 production, may be responsible for prostatic disease, such as benign prostatic hyperplasia and prostate cancer. The data in the present study give rise to the concept that the development and differentiation of UGS in mouse fetuses is very sensitive to fetal exposure to low-dose BPA via the mother. Further investigation of various aspects of BPA-specific action is necessary to fully understand the role of BPA as an EDC.
